4-Amino-1-isobutyl-5-methoxypyrazole | 405548-44-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4-Amino-1-isobutyl-5-methoxypyrazole
• 英文别名: 5-Methoxy-1-(2-methylpropyl)-1H-pyrazol-4-amine；5-methoxy-1-(2-methylpropyl)pyrazol-4-amine
• CAS: 405548-44-9
• 化学式: C₈H₁₅N₃O
• 分子量: 169.227
• InChiKey: QMXMCOGTUBMKMN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  53.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Amino-1-isobutyl-5-methoxypyrazole 、 2-(4-fluoro-3-iodo-1-methyl-1H-indazol-6-yl)propan-2-ol 在 2-(二环己基膦)3,6-二甲氧基-2′,4′,6′-三异丙基-1,1′-联苯 、 [(2-di-cyclohexylphosphino-3,6-dimethoxy-2’,4’,6’-triisopropyl-1,1‘-biphenyl)-2-(2‘-amino-1,1’-biphenyl)]palladium(II) methanesulfonate 、 sodium t-butanolate 作用下， 以 四氢呋喃 为溶剂， 以65.8 mg的产率得到2-(4-fluoro-3-{[5-methoxy-1-(2-methylpropyl)-1H-pyrazol-4-yl]amino}-1-methyl-1H-indazol-6-yl)propan-2-ol
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND

  摘要：

  The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

  公开号：

  US20230322683A1
• 作为产物：
  描述：

  5-methoxy-1-(2-methylpropyl)-4-nitro-1H-pyrazole 生成 4-Amino-1-isobutyl-5-methoxypyrazole
  参考文献：
  名称：

  HETEROCYCLIC COMPOUND

  摘要：

  The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.

  公开号：

  US20230322683A1

文献信息

• 4-ACYLAMINOPYRAZOLE DERIVATIVES
  申请人：Sankyo Company, Limited

  公开号：EP1329160A2

  公开（公告）日：2003-07-23

  A 4-acylaminopyrazole derivative represented by the following general formula: wherein R1 is a hydrogen atom, an optionally substituted C1-C16 alkyl group or the like,    R2 and R3 are independently a hydrogen atom, a halogen atom, an optionally substituted C1-C6 alkyl group or the like, R4 is a hydrogen atom, a C1-C6 alkyl group or a cyano group, Z is an oxygen atom or a sulfur atom, Ar is an optionally substituted C6-C14 aryl group or an optionally substituted 5-6 membered unsaturated heterocyclic group, B is a hydrogen atom, a halogen atom, an optionally substituted C1-C16 alkyl group or the like.

  由以下通式代表的 4-酰氨基吡唑衍生物： 其中 R1 是氢原子、任选取代的 C1-C16 烷基或类似基团、 R2 和 R3 独立地为氢原子、卤素原子、任选取代的 C1-C6 烷基或类似基团、 R4 是氢原子、C1-C6 烷基或氰基、 Z 是氧原子或硫原子、 Ar 是任选取代的 C6-C14 芳基或任选取代的 5-6 位元不饱和杂环基团、 B 是氢原子、卤素原子、任选取代的 C1-C16 烷基或类似基团。
• EP1329160
  申请人：——

  公开号：——

  公开（公告）日：——
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20230322683A1

  公开（公告）日：2023-10-12

  The present invention provides a compound having a cell degeneration inhibitory action, particularly a motor neuron degeneration inhibitory action, which is useful as an agent for the prophylaxis or treatment of motor neuron diseases (e.g., amyotrophic lateral sclerosis, progressive bulbar paralysis, progressive muscular atrophy, primary lateral sclerosis, progressive pseudobulbar paralysis, spinal muscular atrophy, Parkinson's disease, Lewy body dementia, multiple-system atrophy, Friedreich's ataxia) and the like. The present invention relates to a compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof.